The Hillman Cancer Center Animal Facility (AF) is a biomedical research support program, consisting of staff, services, and facilities dedicated to meeting the animal-dependent needs of the research programs of the University of Pittsburgh Cancer Institute (UPCI). The goal ofthe AF is to provide expertise, advice, facilities, personnel, training, and assistance when cancer-related investigations require the use of animal models. Veterinary technical support, animal modeling consultation, and veterinary interpretive pathologic phenotypic support are partial services covered by the AF. The facility occupies 12,228 net sq. ft. in the Hillman Cancer Center Research Pavilion (HCC), and is designed, managed, and dedicated to maintain specific pathogen free (SPF) rodent populations, using barrier and micro-isolator caging systems and techniques. This Shared Facility is an integral component of the University of Pittsburgh's overall Animal Care Program that is overseen by the Institutional Animal Care and Use Committee. This program is registered with the USDA (23-R0016) and maintains a letter of assurance with the Public Health Service ofthe NIH (A3187-01). It is fully accredited by the Association for the Assessment and Accreditation for Laboratory Animal Care International (AAALAC Int.), which was last received in March of 2008.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705405
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$83,344
Indirect Cost
$28,210
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64
Beumer, Jan H; Ding, Fei; Tawbi, Hussein et al. (2016) Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34:110-6

Showing the most recent 10 out of 885 publications